Scientists at several institutions across the country, in partnership with the Multiple Myeloma Research Foundation (MMRF), have helped generate the largest single-cell immune cell atlas of the bone marrow in patients with multiple myeloma. The findings, published by Pilcher et al in Nature Cancer, provide insight on immune dysfunction in multiple myeloma and could lead to improved tools for predicting which patients are at higher risk of relapse after treatment.
The study analyzed nearly 1.5 million immune cells from the bone marrow of 335 newly diagnosed patients in the MMRF’s CoMMpass study dataset, using single-cell RNA sequencing. This approach allowed researchers to examine the molecular features of individual cells, revealing previously hidden patterns in how the immune system behaves in the presence of multiple myeloma.
“Currently, doctors rely heavily on the genetic features of cancer cells to estimate how aggressive their disease is,” said co-senior study author Sacha Gnjatic, PhD, Professor of Immunology and Immunotherapy at the Mount Sinai Tisch Cancer Center. “Our research shows that the immune cells surrounding the tumor are just as important in determining how the disease progresses, and this could lead to earlier, more targeted treatment strategies.”
“The scale and maturity of the MMRF’s CoMMpass study and the breadth of this multicenter collaboration highlights the importance of creating ‘big science’ teams,” added George Mulligan, PhD, co-senior author and Chief Scientific Officer at the MMRF.
The team discovered that some patients whose disease relapsed quickly after initial therapy had distinct immune cell populations in their bone marrow at the time of diagnosis. Notably, a subset of T cells appeared to show a state of immunosenescence, meaning they were present but not functioning effectively and contributing to immune suppression. In addition, the study uncovered patterns of communication between immune cells and cancer cells that may support tumor growth.
These insights suggest that the immune system’s response to multiple myeloma could be used as a predictive tool, offering a complementary layer to traditional genetic testing. While the current technology used in the study is primarily for research, the investigators hope the findings will inform the development of simple, broadly available tests in the future.
“This work not only provides new biological insights, but also lays the groundwork for future discoveries,” Dr. Gnjatic said. “It could help researchers around the world better understand how the immune system interacts with cancer and ultimately, help improve outcomes for patients.”
The large patient sample size and robust clinical annotations—enabled by the MMRF’s extensive biorepository and 12 years of patient data—make this one of the most comprehensive resources of its kind. This report will significantly contribute to our understanding of immune function in multiple myeloma.
DISCLOSURE: The MMRF designed and funded this collaborative research, which involved equal contribution from scientists at Mount Sinai, Emory University, Beth Israel Deaconess Medical Center, Washington University in St. Louis’s Siteman Cancer Center, the Mayo Clinic, and the MMRF. For full disclosures of the study authors, visit nature.com.
